ESSA Pharma Inc - Asset Resilience Ratio
ESSA Pharma Inc (EPIX) has an Asset Resilience Ratio of 21.42% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ESSA Pharma Inc (EPIX) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how ESSA Pharma Inc's Asset Resilience Ratio has changed over time. See how leveraged is ESSA Pharma Inc's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down ESSA Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ESSA Pharma Inc (EPIX) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $23.67 Million | 21.42% |
| Total Liquid Assets | $23.67 Million | 21.42% |
Asset Resilience Insights
- Good Liquidity Position: ESSA Pharma Inc maintains a healthy 21.42% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
ESSA Pharma Inc Industry Peers by Asset Resilience Ratio
Compare ESSA Pharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for ESSA Pharma Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for ESSA Pharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-09-30 | 17.99% | $23.05 Million | $128.11 Million | -58.71pp |
| 2023-09-30 | 76.70% | $114.37 Million | $149.12 Million | +11.71pp |
| 2022-09-30 | 64.99% | $110.16 Million | $169.50 Million | +36.17pp |
| 2021-09-30 | 28.82% | $57.10 Million | $198.17 Million | +1.50pp |
| 2020-09-30 | 27.32% | $22.01 Million | $80.58 Million | -- |
| 2018-09-30 | 0.00% | $0.00 | $16.02 Million | -- |
| 2017-09-30 | 0.00% | $0.00 | $5.61 Million | -- |
| 2016-09-30 | 0.00% | $0.00 | $10.40 Million | -- |
| 2015-09-30 | 0.00% | $0.00 | $7.49 Million | -- |
| 2014-09-30 | 0.00% | $0.00 | $4.20 Million | -- |
About ESSA Pharma Inc
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada. As of October 9, 2025, ESSA Pharma Inc. operates as a subsidiary of Alexis Bio, Inc.